| 2025-08-19 |
详情>>
股本变动：
变动后总股本2933.42万股
|
| 2025-08-19 |
详情>>
业绩披露：
2025年中报每股收益-6.67美元,归母净利润-1996.1万美元,同比去年增长-1005.87%
|
| 2025-08-08 |
股东大会：
将于2025-08-28召开股东大会
会议内容 ▼▲
- 1.Approve the issuance of the Series D Convertible Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the conversion of our Series D Preferred Stock, with an initial conversion price of $1.368;
2.Approve the issuance of the Note Conversion Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the conversion of the Promissory Notes, at an initial conversion price of $0.587;
3.Approve the issuance of the PIPE Warrant Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the exercise of the PIPE Warrants, at an initial exercise price of $0.587 or $1.10;
4.Approve the issuance of the Series E Convertible Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the conversion of our Series E Preferred Stock, at an initial conversion price of $0.30;
5.Approve the issuance of the Series E Warrant Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the exercise of the Series E Warrants, with an initial exercise price of $0.75;
6.Approve the issuance of the ELOC Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), pursuant to the ELOC Purchase Agreement, establishing an equity line of credit;
7.Approve an amendment of the Company’s Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation, to increase the number of authorized shares of capital stock from 125,000,000 shares to 1,000,000,000 shares;
8.Approve an amendment of the 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,599,180 shares;
9.Approve an amendment of the Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio of no less than 1-for-2 and not greater than 1-for-25, with the exact ratio within such range and the timing of such reverse stock split to be determined at the sole discretion of our board of directors, or the Board;
10.Approve adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding proposals or to establish a quorum.
11.Transact any other business that may properly come before the Special Meeting or any adjournment or postponement of the Special Meeting.
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-4.63美元,归母净利润-504.3万美元,同比去年增长-149.35%
|
| 2025-04-15 |
详情>>
业绩披露：
2024年年报每股收益-104.35美元,归母净利润-548.7万美元,同比去年增长72.96%
|
| 2025-02-21 |
复牌提示：
2025-02-20 19:50:00 停牌，复牌日期 2025-02-21 09:00:00
|
| 2025-02-21 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2025-01-08 |
股东大会：
将于2025-02-03召开股东大会
会议内容 ▼▲
- 1.Approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our outstanding shares of common stock, par value $0.001 per share (“Common Stock”), by a ratio of any whole number between 1-for-5 and 1-for-50, the implementation and timing of which shall be subject to the discretion of our Board of Directors (the “Board”);
2.Approve an amendment to our Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan (the “A&R 2020 Plan”) to increase the number of shares of Common Stock authorized for issuance under the A&R 2020 Plan from 41,010 shares to 1,141,010 shares;
3.Approve adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding proposals or to establish a quorum.
|
| 2024-11-26 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-8.64美元,归母净利润-555.5万美元,同比去年增长63.30%
|
| 2024-10-08 |
详情>>
内部人交易：
Fraser Craig股份增加5431.00股
|
| 2024-09-03 |
股东大会：
将于2024-09-24召开股东大会
会议内容 ▼▲
- 1.Elect the four director nominees that are set forth in the attached Proxy Statement to serve as directors, whose term will expire in 2025
2.Approve, on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement
3.Ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the 2024 fiscal year
4.Approve the issuance of shares of common stock, in accordance with Nasdaq Listing Rule 5635(d) pursuant to the Committed Equity Financing (as defined herein)
5.Approve the issuance of shares of common stock in accordance with Nasdaq Listing Rule 5635(d), upon (i) the conversion of our Series C Convertible Preferred Stock, par value $0.001 per share, or Series C Convertible Preferred Stock, with an initial conversion price of $3.74, which is subject to adjustment to no lower than $1.28 per share, and (ii) the exercise of warrants to purchase common stock issued in connection therewith, with an initial exercise price of $4.11, subject to customary adjustments
6.Any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-08-19 |
详情>>
业绩披露：
2024年中报每股收益-3.47美元,归母净利润-180.5万美元,同比去年增长83.15%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益21.98美元,归母净利润1021.90万美元,同比去年增长348.58%
|
| 2024-04-19 |
详情>>
拆分方案：
每18.0000合并分成1.0000股
|
| 2024-04-16 |
详情>>
业绩披露：
2023年年报每股收益-5.24美元,归母净利润-2029.1万美元,同比去年增长48.25%
|
| 2024-03-12 |
股东大会：
将于2024-04-10召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Charter to effect a reverse stock split of our outstanding shares of Common Stock by a ratio of any whole number between 1-for-5 and 1-for-25, the implementation and timing of which shall be subject to the discretion of our Board (the “Reverse Stock Split Proposal”);
2.To approve adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding proposal or to establish a quorum (the “Adjournment Proposal”).
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-4.5美元,归母净利润-1513.7万美元,同比去年增长48.72%
|
| 2023-08-07 |
详情>>
业绩披露：
2023年中报每股收益-4.36美元,归母净利润-1071.2万美元,同比去年增长57.93%
|
| 2023-06-30 |
股东大会：
将于2023-08-15召开股东大会
会议内容 ▼▲
- 1.Elect the five director nominees that are set forth in the attached Proxy Statement to serve as directors, whose term will expire in 2024;
2.Approve, on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement;
3.Ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the 2023 fiscal year;
4.Approve the amendment and restatement of our Amended and Restated Windtree Therapeutics 2020 Equity Incentive Plan, or the 2020 Plan, including an increase to the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan from 93,175 shares to 738,175 shares.
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-4.76美元,归母净利润-411.1万美元,同比去年增长49.42%
|
| 2023-02-24 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2023-01-10 |
股东大会：
将于2023-02-07召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our outstanding shares of common stock, par value $0.001 per share ( “Common Stock”) by a ratio of any whole number between 1-for-20 and 1-for-50,the implementation and timing of which shall be subject to the discretion of our Board of Directors (the “Board”);
2.To approve adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding proposal.
|
| 2022-05-11 |
股东大会：
将于2022-06-07召开股东大会
会议内容 ▼▲
- 1.to elect the five director nominees that are set forth in the attached Proxy Statement to serve as directors, whose term will expire in 2023;
2.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement;
3.to ratify the selection of EisnerAmper LLP as our independent registered public accounting firm for the 2022 fiscal year.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.to elect the six director nominees that are set forth in the attached Proxy Statement to serve directors, whose term will expire in 2022;
2.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement;
3.to indicate, on an advisory basis, the preferred frequency with which future advisory votes on the compensation of our named executive officers should be held;
4.to ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the 2021 fiscal year.
|
| 2017-05-18 |
股东大会：
将于2017-06-30召开股东大会
会议内容 ▼▲
- 1. To elect five members to our Board of Directors (“Board”) to serve until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified, or until their earlier resignation or removal
2. To ratify the selection of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2017
3. To amend our Amended and Restated Windtree Therapeutics, Inc. 2011 Long-Term Incentive Plan, as amended (“2011 Plan”), to increase the number of shares of common stock, par value $.001 per share available for issuance under the 2011 Plan from 1,978,572 shares to 2,728,572 shares
4. To amend our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, par value $.001 per share available for issuance by the Company from 60 million to 120 million
5. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this Proxy Statement
|
| 2016-05-24 |
股东大会：
将于2016-06-21召开股东大会
会议内容 ▼▲
- 1.To elect five members to our Board of Directors (“Board”) to serve until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified, or until their earlier resignation or removal;
2.To ratify the selection of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2016;
3.To amend our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, par value $.001 per share available for issuance by the Company from 36 million to 60 million;
4.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement;
5.To transact such other business as may properly come before the meeting and any adjournments or postponements thereof.
|
| 2015-12-14 |
股东大会：
将于2016-01-21召开股东大会
会议内容 ▼▲
- 1.To authorize the Board of Directors of the Company (the “Board”), in its sole discretion, to effect a share consolidation, or reverse split (“reverse split”), of our common stock, par value $.001 per share (“Common Stock”), by filing an Amendment to our Amended and Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”), at any time through December 31, 2016, at an exchange ratio of not less than 1-for-10 and not greater than 1-for-20, as determined by the Board in its sole discretion. The Board will retain the discretion to determine whether or not to implement a reverse split through December 31, 2016 (Proposal 1);
2.If and only if Proposal 1 is approved by stockholders, to authorize the Board in conjunction with a reverse split to reduce the number of authorized shares of Common Stock available for issuance from 250 million shares to a number that equals the number set forth opposite the exchange ratio applied in the reverse split in the table included on page 5 of this Proxy Statement, by filing an Amendment to our Certificate of Incorporation at any time through December 31, 2016. For example, if a 1-for-10 reverse split is implemented, the authorized shares will be reduced from 250 million to 50 million shares (Proposal 2);
3.If and only if Proposal 1 is approved by stockholders, to approve the Amended and Restated Discovery Laboratories, Inc. 2011 Long-Term Incentive Plan (“Restated 2011 Plan”) to authorize the issuance of additional shares under the 2011 Long-Term Incentive Plan in an amount that equals the number set forth opposite the exchange ratio applied in the reverse split in the table included on page 18 of this Proxy Statement, and approve the Restated 2011 Plan for purposes of Section 162 of the Internal Revenue Code for an additional five years (Proposal 3);
4.To authorize an adjournment of the Special Meeting (as may be determined by the Board), if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of any of Proposals 1 through 3 (Proposal 4)
|